Back to Dividend Stocks
AbbVie Inc. (ABBV) logo
ABBV|Healthcare|Drug Manufacturers - General|$201.55|P/E 98.3|MCap 356.5B|NYSE

Last update: May 9, 2026 at 09:32

Dividend Safety Rating

54/ 100Caution

ABBV's dividend shows some areas that warrant monitoring. Strengths include a 53.2% fcf payout ratio & 31.6% operating margin. Areas of concern: 326.0% earnings payout ratio & 0.7x current ratio. As a Dividend Aristocrat with 25+ consecutive years of increases, ABBV has a proven commitment to shareholders.

Based on 15 of 15 metrics

Strengths

  • Operating Margin: 31.6%Healthy operating margin provides a wide buffer.
  • Gross Margin: 72.6%High gross margin signals strong pricing power.
  • Dividend Streak: Aristocrat (25+ yrs)Long, uninterrupted dividend track record.

Risks

  • Earnings Payout Ratio: 326.0%High earnings payout ratio leaves little safety margin.
  • Current Ratio: 0.7xLimited short-term liquidity to meet obligations.
  • Debt-to-Equity: -21.2Debt-to-equity is elevated for the sector.

Payout & Coverage

Caution
Earnings Payout Ratio
326.0%Danger
FCF Payout Ratio
53.2%Safe
CFO Payout Ratio
58.5%Caution
Interest Coverage
3.3xCaution

Balance Sheet

Warning
Net Debt / Total Assets
46.5%Caution
Current Ratio
0.7xDanger
Debt-to-Equity
-21.2Danger

Profitability

Caution
Return on Equity
-129.7%Danger
Operating Margin
31.6%Very Safe
Gross Margin
72.6%Very Safe
Profit Margin Stability
VolatileWarning

Dividend Track Record

Very Safe
Dividend Streak
Aristocrat (25+ yrs)Very Safe
Dividend Cut
NoneVery Safe
5-Year Dividend CAGR
6.8%Safe
Earnings Stability
StableSafe

About AbbVie Inc.

AbbVie Inc. is a research-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines and therapies worldwide. Headquartered in North Chicago, Illinois, and founded in 2012 as a spin-off from Abbott Laboratories, it employs approximately 55,000 people and operates primarily in the pharmaceuticals and biotechnology sector. Key products include Humira, a leading treatment for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis; Skyrizi and Rinvoq for immunology indications like plaque psoriasis and ulcerative colitis; Imbruvica for blood cancers; and Botox for neurological conditions and aesthetics following the 2020 Allergan acquisition. AbbVie Inc. maintains a robust pipeline addressing immunology, oncology, neuroscience, and other therapeutic areas, with recent advancements in treatments for essential tremor and kidney disease. Its global presence underscores its significant role in advancing healthcare solutions and contributing to the biopharmaceutical industry's growth.

Dividend Overview

Dividend Yield

3.35%

Annual Dividend

$6.74

Frequency

Quarterly

Payout Ratio

325.98%

FCF Payout Ratio

53.19%

Stock Price

$201.55

52-Week Range

$176.57 $244.81

Dividend History (2016–2025)

ABBV annual dividend per share and yield history

Earnings & Profitability

ABBV earnings per share and net profit margin

Key Dates

Last Ex-Dividend Date

April 15, 2026

Next Payment Date

May 15, 2026

Dividend Growth

3-Year Dividend CAGR

5.17%

5-Year Dividend CAGR

6.81%

10-Year Dividend CAGR

12.50%

3-Year Total Growth

16.31%

5-Year Total Growth

38.98%

10-Year Total Growth

224.75%

Dividend Aristocrat (25+ yrs)

This company has increased its dividend for 25+ consecutive years.

Income Calculator

ABBV Dividend Calculator

Total Investment

$20,155.00

Annual Income

$674.00

Quarterly Income

$168.50

Monthly Income

$56.17

Similar Dividend Stocks

StockYield5Y CAGRPrice
AbbVie Inc. (ABBV) logo
ABBV
3.35%6.81%$201.55
Amgen Inc. (AMGN) logo
AMGN
2.95%8.27%$331.70
Gilead Sciences Inc. (GILD) logo
GILD
2.43%3.04%$131.33
Johnson & Johnson (JNJ) logo
JNJ
2.29%5.25%$221.32
Merck & Co., Inc. (MRK) logo
MRK
2.98%6.75%$111.38
Pfizer Inc. (PFE) logo
PFE
6.70%3.59%$25.68
UnitedHealth Group Incorporated (UNH) logo
UNH
2.33%12.57%$379.98

Frequently Asked Questions

What is ABBV's current dividend yield?
AbbVie Inc. (ABBV) currently has a dividend yield of 3.35%, based on a stock price of $201.55 and an annual dividend of $6.74.
When is ABBV's next dividend payment date?
ABBV's next ex-dividend date is 2026-04-15 and the next payment date is 2026-05-15. You must own the stock before the ex-dividend date to receive the upcoming payment.
How much does ABBV pay in dividends per year?
AbbVie Inc. paid $6.56 per share in annual dividends in 2025. The dividends are paid quarterly.
Has ABBV been increasing its dividend?
Yes, AbbVie Inc. is a Dividend Aristocrat (25+ yrs). Its dividend has grown at a 5-year CAGR of 6.81%, a 3-year CAGR of 5.17% and a 10-year CAGR of 12.50%.
Is ABBV's dividend safe?
AbbVie Inc. has a payout ratio of 325.98%. Its free cash flow payout ratio is 53.19%. The payout ratio is above 100%, which may indicate the company is paying more in dividends than it earns. This could be unsustainable long-term.
How is ABBV's Dividend Safety Rating calculated?
The Dividend Safety Rating evaluates AbbVie Inc.'s dividend sustainability across four categories: Payout & Coverage (30%), Balance Sheet (20%), Profitability (20%), and Dividend Track Record (30%). Each metric is rated from "Very Safe" to "Danger" based on industry-standard thresholds, with sector-specific adjustments for healthcare companies. The overall score ranges from 0 to 100.

Want to understand how we rate dividend safety? Read our full methodology

Track ABBV Dividends with OnlyDividends

What will ABBV actually pay you after taxes? Track every payout, get notified on payment dates, and stop guessing.

This page is not investment advice. The content is for informational purposes only and should not be construed as a recommendation to buy, sell, or hold any security. Always do your own research and consult a qualified financial advisor before making investment decisions.

Financial data, including dividend history, earnings, balance sheet metrics, and the Dividend Safety Rating, is provided for informational purposes only. Data may be delayed or differ from official filings. Past performance does not guarantee future results. Always verify with official sources before making investment decisions.

Market data provided by Twelve Data.